Markets:

Overview

News

Currencies

International

Treasuries

Intra-Cellular Therapies Inc. - Common Stock (NQ:ITCI)

131.87 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intra-Cellular Therapies Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Patterson Companies, Silk Road Medical, Micron, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday ↗

June 18, 2024

Via Benzinga

Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study ↗

June 18, 2024

Intra-Cellular Therapies reports positive topline results for Study 502 on lumateperone 42 mg as adjunctive therapy for major depressive disorder. FDA application expected in H2 2024.

Via Benzinga

Intra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 Win ↗

June 18, 2024

The company hopes to expand its antipsychotic drug to depression treatment.

Via Investor's Business Daily

Where Intra-Cellular Therapies Stands With Analysts ↗

June 12, 2024

Via Benzinga

The Secret Stock Stash: 3 Overlooked Picks That Belong in Every Portfolio ↗

May 30, 2024

While it’s comforting to pick the ideas of the masses, these overlooked stocks may offer superior upside potential for the daring.

Via InvestorPlace

Analyst Ratings For Intra-Cellular Therapies ↗

May 08, 2024

Via Benzinga

The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts ↗

April 22, 2024

Via Benzinga

How Is The Market Feeling About Intra-Cellular Therapies? ↗

April 19, 2024

Via Benzinga

ITCI Stock Earnings: Intra-Cellular Therapies Beats EPS, Beats Revenue for Q1 2024 ↗

May 07, 2024

ITCI stock results show that Intra-Cellular Therapies beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

3 Biotech Stocks With Skyrocketing Potential: April 2024 ↗

April 24, 2024

These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time.

Via InvestorPlace

Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review ↗

April 19, 2024

The Nasdaq and S&P 500 tumbled below their 50-day lines.

Via Investor's Business Daily

Topics Stocks

Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday ↗

April 17, 2024

With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

8 Analysts Assess Intra-Cellular Therapies: What You Need To Know ↗

April 03, 2024

Via Benzinga

Where Intra-Cellular Therapies Stands With Analysts ↗

February 23, 2024

Via Benzinga

Analyst Scoreboard: 8 Ratings For Intra-Cellular Therapies ↗

January 18, 2024

Via Benzinga

In-Depth Examination Of 6 Analyst Recommendations For Intra-Cellular Therapies ↗

January 02, 2024

Via Benzinga

Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

April 16, 2024

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 16, 2024

Via Benzinga

Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study ↗

April 16, 2024

Unlock new hope for major depressive disorder with Lumateperone 42 mg. Results from Intra-Cellular's Study 501, show significant symptom relief as adjunctive therapy to antidepressants.

Via Benzinga

Expert Ratings for Intra-Cellular Therapies ↗

December 11, 2023

Via Benzinga

Intra-Cellular Therapies's Earnings: A Preview ↗

November 01, 2023

Via Benzinga

UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday ↗

April 16, 2024

U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday.

Via Benzinga

Topics Stocks

Intra-Cellular Therapies Inc. (NASDAQ: ITCI) Climbs to New 52-Week High

April 16, 2024

Via Investor Brand Network

Intra-Cellular Therapies Stock Launches 20% Into Breakout Territory On Depression Test Results ↗

April 16, 2024

Intra-Cellular Therapies is trying to position its antipsychotic in depression treatment.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 16, 2024

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

April 04, 2024

Via Benzinga

3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition ↗

February 21, 2024

Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.

Via InvestorPlace

Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals

December 29, 2023

Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.

Via MarketBeat

10 Health Care Stocks Whale Activity In Today's Session ↗

December 14, 2023

Via Benzinga

Are These Biotechs Ready To Launch? ↗

December 09, 2023

Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.